The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide.

Autor: Mariotti J; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy. jacopo.mariotti@cancercenter.humanitas.it., Granata A; Department of Hematology, Transplantation Program, Marseille, France., Bramanti S; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy., Devillier R; Department of Hematology, Transplantation Program, Marseille, France., Furst S; Department of Hematology, Transplantation Program, Marseille, France., Sarina B; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy., Harbi S; Department of Hematology, Transplantation Program, Marseille, France., Legrand F; Department of Hematology, Transplantation Program, Marseille, France., Faucher C; Department of Hematology, Transplantation Program, Marseille, France., Weiller PJ; Department of Hematology, Transplantation Program, Marseille, France., Chabannon C; Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France.; Aix-Marseille Université, Marseille, France.; Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France., Carlo-Stella C; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy.; Humanitas University, Humanitas Clinical and Research Hospital, Rozzano, Italy., Santoro A; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy.; Humanitas University, Humanitas Clinical and Research Hospital, Rozzano, Italy., Blaise D; Department of Hematology, Transplantation Program, Marseille, France.; Aix-Marseille Université, Marseille, France.; Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France., Castagna L; Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2019 Jul; Vol. 54 (7), pp. 1164-1167. Date of Electronic Publication: 2019 Jan 24.
DOI: 10.1038/s41409-019-0453-0
Abstrakt: We propose to test whether the new refined Minnesota risk score, which represents a new tool for acute Graft-versus-Host-Disease (aGVHD) grading, may be useful to predict the final outcome of patients with aGVHD after haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy). Hundred consecutive patients with grade 2-4 aGVHD were included. Twenty-two percent of the patients had high-risk (HR) aGVHD and had a lower chance to respond at day 28: 41% of non-responders (NR) were in the HR vs 13% in the standard-risk (SR) group (p = 0.003). By multivariate analysis, grade 3-4 aGVHD according to the traditional Keystone classification was the main independent predictor of non-response to front-line treatment at day 28, while HR aGVHD by the new refined Minnesota score remained the main independent variable associated with adverse NRM and OS. The new Minnesota refined risk score is a useful tool to predict the outcome of patients with aGVHD after Haplo-SCT with PT-Cy. Due to the few patients exchanging between categories in the two classifications, it is not possible to discriminate which system better predicts the outcome of patients with aGVHD in the setting of Haplo-SCT. Extending these preliminary observations to a larger cohort is warranted.
Databáze: MEDLINE
Externí odkaz: